Kate Therapeutics

Kate Therapeutics

  • Founded: 2020
  • Location: San Diego, CA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy
  • Drug types: MUS, GEN
  • Lead product: various
  • Product link: https://www.katetherapeutics.com/pipeline/
  • Funding: $51M A Jun 2023
  • Investors: Westlake Village BioPartners, Versant Ventures, Osage University Partners, UF Innovate | Ventures



job board

Short description:

AAV-based gene therapy for muscle disease

Drug notes:

Contact us to add description: recruit@workinbiotech.com

Long description:

Kate Therapeutics is developing adeno-associated virus (AAV)-based gene therapies to treat muscle and heart diseases. The current limitations with gene therapies include tissue-specific delivery, liver detargeting and gene regulation. Kate is applying their novel technology platforms to improve the safety and efficacy of AAV gene therapy: this includes their novel capsids that provide superior muscle and heart transduction compared to naturally occurring serotypes that are currently used in clinical trials. With these advances, Kate is establishing a pipeline of muscle and cardiac disease indications that can be addressed with their capsid and cargo technologies.


Kate Therapeutics
Scientist– Cardiovascular Drug Discovery, Gene The...
San Diego, US|40 days ago
Kate Therapeutics
Director, Human Resources
San Diego, US|41 days ago
Kate Therapeutics
Senior/Executive Director – Nonclinical Developmen...
San Diego, US|54 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com